Full Text View
Tabular View
No Study Results Posted
Related Studies
Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies
This study is ongoing, but not recruiting participants.
Study NCT00943592   Information provided by University of Chicago

First Received on July 20, 2009.   Last Updated on July 8, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Advanced Hematologic Malignancies
Leukemia
Preleukemia
Additional conditions recognized in this trial
Hematologic Neoplasms
Myelodysplastic Syndromes
Neoplasms
More general conditions related to this trial
Bone Marrow Diseases
Hematologic Diseases
Neoplasms by Histologic Type
Neoplasms by Site
Precancerous Conditions
Interventions listed in this trial
Clofarabine
Melphalan
Campath
Stem Cell Transplant
Additional drug interventions recognized in this trial
Alemtuzumab
Campath 1G
More general drug interventions related to this trial
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
University of Chicago


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services